Clinical Report: Quantitative CT Assessment of Short-term Changes in GGNs

Overview

This study evaluates the short-term changes in synchronous ground-glass nodules (GGNs) in lung cancer patients undergoing immune checkpoint inhibitor (ICI) therapy. Findings indicate that GGNs in the ICI group showed regression compared to a control group, with shifts in volume change proportion and Lung-RADS categories.

Background

The detection of synchronous GGNs in lung cancer patients has increased due to the use of ICIs. Understanding the behavior of these nodules during treatment is crucial to avoid overtreatment while ensuring timely intervention for potentially malignant lesions. This study aims to provide insights into the longitudinal changes of GGNs during ICI therapy.

Data Highlights

Key Findings

• Nodules in the ICI group showed a higher regression rate compared to the control group (23.6% vs. 1.8%, p< 0.001).
• Improvement in Lung-RADS category was more common in the ICI group (8.2% vs. 1.8%; p = 0.018).
• GGNs in the ICI group had lower monthly increases in diameter, volume, surface area, and mass compared to controls.
• Within the ICI group, nodules exhibited a significant reduction in diameter and increases in mean CT value and solid component proportion.
• Part-solid nodules showed larger volume reductions than pure GGNs.
• Nodules with Lung-RADS ≥ 4A demonstrated significant decreases in entropy.

Clinical Implications

The findings suggest that ICI therapy may lead to favorable changes in the growth patterns of synchronous GGNs, which could influence monitoring strategies. Clinicians should consider these changes when evaluating the management of GGNs in lung cancer patients receiving ICIs.

Conclusion

This study highlights the potential for ICI therapy to alter the growth dynamics of synchronous GGNs in lung cancer patients, indicating a need for further research in this area.

Related Resources & Content

1. Heyward et al., JAMA Oncology, 2024 -- Harm-Benefit Balance of Immune Checkpoint Inhibitor Treatment in Non–Small Cell Lung Cancer
2. Frontiers in Immunology, 2026 -- Early prediction of immune checkpoint inhibitor-related pneumonitis in advanced non-small cell lung cancer based on primary tumor Delta-radiomics features
3. European Radiology, 2022 -- CT-based Quantitative Assessment of Lung Tissue to Enhance Malignancy Risk Evaluation in Incidental Pulmonary Nodules
4. The ASCO Post — Deep-Learning CT Biomarker Predicts Survival Better Than Traditional Measures in Immunotherapy-Treated Advanced NSCLC
5. Update to ASCO Living Guideline for NSCLC Without Driver Alterations Includes First Comparison of Immunotherapy Options
6. Clinical Outcomes of Ground-Glass Nodules Detected in a CT Lung Cancer Screening Program
7. Imaging Response Criteria - NCI